RE: Media and PR12 Apr 2022 09:03
Drug ready for cancer test
Scancell Holdings shares hit a two-month high yesterday after the drugs maker said it was recruiting patients to test its cancer treatment on.
It will be the first clinical trial for the drug Modi-1 on humans. It will assess Modi-1 in four cancer types, including triple-negative breast, ovarian, head and neck, and renal.
Scancell’s Modi-1 will be assessed against four cancer types
Scancell’s Modi-1 will be assessed against four cancer types
The Nottingham-based group said oncology research sites and investigators across the UK have agreed to contribute patients to the study, with the first wave of clinical sites open for recruitment. Scancell expects up to 20 sites to be recruiting.
The UK’s Medicines and Healthcare products Regulatory Agency approved a study protocol modification that should speed recruitment as well as shorten the study’s overall timeline.
Lindy Durrant, Scancell’s chief executive, said recruitment marked a “major step forward”.
“We are very excited about the prospects for Modi-1 based on the dramatic regression of large tumours in our preclinical models and look forward to accelerating recruitment and analysing early safety and immunogenicity data later this year.”
The shares rose 6¼p, or 57.2 per cent, to close at 17p.